| Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children H Visscher, CJD Ross, SR Rassekh, A Barhdadi, MP Dubé, H Al-Saloos, ... Journal of clinical oncology 30 (13), 1422-1428, 2012 | 448 | 2012 |
| Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston … PR Brock, KR Knight, DR Freyer, KCM Campbell, PS Steyger, BW Blakley, ... Journal of Clinical Oncology 30 (19), 2408-2417, 2012 | 441 | 2012 |
| Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy CJD Ross, H Katzov-Eckert, MP Dubé, B Brooks, SR Rassekh, ... Nature genetics 41 (12), 1345-1349, 2009 | 368 | 2009 |
| A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer F Aminkeng, AP Bhavsar, H Visscher, SR Rassekh, Y Li, JW Lee, ... Nature genetics 47 (9), 1079-1084, 2015 | 275 | 2015 |
| Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicity F Aminkeng, CJD Ross, SR Rassekh, S Hwang, MJ Rieder, AP Bhavsar, ... British journal of clinical pharmacology 82 (3), 683-695, 2016 | 236 | 2016 |
| Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children H Visscher, CJD Ross, SR Rassekh, GSS Sandor, HN Caron, ... Pediatric blood & cancer 60 (8), 1375-1381, 2013 | 214 | 2013 |
| Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin‐Induced Hearing Loss in Children K Pussegoda, CJ Ross, H Visscher, M Yazdanpanah, B Brooks, ... Clinical Pharmacology & Therapeutics 94 (2), 243-251, 2013 | 144 | 2013 |
| Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ... Molecular Case Studies 1 (1), a000570, 2015 | 131 | 2015 |
| Genetic Variants in SLC22A17 and SLC22A7 are Associated With Anthracycline-Induced Cardiotoxicity in Children H Visscher, SR Rassekh, GS Sandor, HN Caron, EC Van Dalen, ... Pharmacogenomics 16 (10), 1065-1076, 2015 | 123 | 2015 |
| Personalizing the treatment of pediatric medulloblastoma: polo-like kinase 1 as a molecular target in high-risk children J Triscott, C Lee, C Foster, B Manoranjan, MR Pambid, R Berns, ... Cancer research 73 (22), 6734-6744, 2013 | 111 | 2013 |
| Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR M Alcaide, M Cheung, J Hillman, SR Rassekh, RJ Deyell, G Batist, ... Scientific reports 10 (1), 12564, 2020 | 100 | 2020 |
| Long-term outcomes and complications in pediatric Ewing sarcoma SN Hamilton, R Carlson, H Hasan, SR Rassekh, K Goddard American journal of clinical oncology 40 (4), 423-428, 2017 | 84 | 2017 |
| Outcome of infants and young children with newly diagnosed ependymoma treated on the “Head Start” III prospective clinical trial R Venkatramani, L Ji, J Lasky, K Haley, A Judkins, S Zhou, R Sposto, ... Journal of neuro-oncology 113, 285-291, 2013 | 81 | 2013 |
| Pharmacogenomics of vincristine‐induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes GEB Wright, U Amstutz, BI Drögemöller, J Shih, SR Rassekh, MR Hayden, ... Clinical Pharmacology & Therapeutics 105 (2), 402-410, 2019 | 73 | 2019 |
| Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients M Science, PD Robinson, T MacDonald, SR Rassekh, LL Dupuis, L Sung Pediatric Blood & Cancer 61 (3), 393-400, 2014 | 72 | 2014 |
| Clinical practice recommendations for the management and prevention of cisplatin-induced hearing loss using pharmacogenetic markers JW Lee, K Pussegoda, SR Rassekh, JG Monzon, G Liu, S Hwang, ... Therapeutic drug monitoring 38 (4), 423-431, 2016 | 65 | 2016 |
| Antidepressant use among survivors of childhood, adolescent and young adult cancer: a report of the Childhood, Adolescent and Young Adult Cancer Survivor (CAYACS) Research Program RJ Deyell, M Lorenzi, S Ma, SR Rassekh, JP Collet, JJ Spinelli, ... Pediatric blood & cancer 60 (5), 816-822, 2013 | 65 | 2013 |
| Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study DJ Moke, C Luo, J Millstein, KR Knight, SR Rassekh, B Brooks, CJD Ross, ... The Lancet Child & adolescent health 5 (4), 274-283, 2021 | 61 | 2021 |
| Comparison of hypersensitivity rates to intravenous and intramuscular PEG‐asparaginase in children with acute lymphoblastic leukemia: a meta‐analysis and systematic review H Hasan, OM Shaikh, SR Rassekh, AF Howard, K Goddard Pediatric blood & cancer 64 (1), 81-88, 2017 | 61 | 2017 |
| Childhood, adolescent, and young adult cancer survivors research program of British Columbia: objectives, study design, and cohort characteristics ML McBride, PC Rogers, SB Sheps, V Glickman, AM Broemeling, ... Pediatric blood & cancer 55 (2), 324-330, 2010 | 61 | 2010 |
